OKAY
833230
CHANGFU CO.,LTD
871396
Gansu Longshenrongfa Pharmaceutical Industry
300534
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total operating revenue | 1.96%1.99B | 4.69%1.23B | 28.24%808.71M | -7.86%242.71M | 53.05%1.95B | 43.60%1.17B | 10.47%630.64M | 132.12%263.4M | 67.41%1.27B | 66.06%815.38M |
Operating revenue | 1.96%1.99B | 4.69%1.23B | 28.24%808.71M | -7.86%242.71M | 53.05%1.95B | 43.60%1.17B | 10.47%630.64M | 132.12%263.4M | 67.41%1.27B | 66.06%815.38M |
Other operating revenue | 162.77%3.23M | ---- | 894.42%450.3K | ---- | -57.01%1.23M | ---- | -96.25%45.28K | ---- | --2.86M | ---- |
Commission income | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
Premiums earned | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
Total operating cost | 0.69%1.58B | 4.44%984.82M | 23.04%640.49M | -7.45%215.28M | 52.54%1.57B | 41.82%942.94M | 14.17%520.57M | 132.03%232.6M | 83.16%1.03B | 80.40%664.87M |
Operating cost | -3.98%1.32B | -0.34%809.29M | 20.50%533.45M | -16.51%163.28M | 51.54%1.38B | 41.14%812.05M | 9.15%442.7M | 151.59%195.58M | 92.00%907.36M | 89.02%575.35M |
Operating tax surcharges | 240.43%26.53M | 60.55%7.42M | 50.23%4.32M | 25.35%1.78M | 75.47%7.79M | 66.00%4.62M | 57.44%2.88M | 87.11%1.42M | 36.89%4.44M | 12.39%2.78M |
Operating expense | -31.45%28.99M | -9.81%28.2M | -13.70%18.14M | 14.11%12M | 44.60%42.29M | 52.90%31.26M | 81.75%21.02M | 117.70%10.52M | 44.02%29.24M | 66.05%20.45M |
Administration expense | -1.50%78.96M | 3.79%58.71M | 12.60%40.3M | 18.32%20.12M | 29.72%80.16M | 26.24%56.56M | 27.10%35.79M | 16.76%17.01M | 62.57%61.8M | 66.81%44.81M |
Financial expense | 344.26%62.92M | 1,003.47%45.04M | 1,053.51%25.11M | 1,216.49%10.2M | 509.06%14.16M | 286.33%4.08M | 53.41%-2.63M | 6.97%-913.73K | -136.88%-3.46M | -127.80%-2.19M |
-Interest expense (Financial expense) | 151.14%77.16M | 265.51%57.06M | 787.20%34.55M | ---- | 228.80%30.72M | 95.12%15.61M | -36.83%3.89M | ---- | -41.67%9.34M | -34.64%8M |
-Interest Income (Financial expense) | 11.86%-14.78M | -6.73%-12.49M | -43.94%-9.59M | ---- | -23.65%-16.77M | -6.77%-11.7M | 44.44%-6.66M | ---- | -100.16%-13.56M | -144.78%-10.96M |
Research and development | 24.01%65.42M | 5.28%36.17M | -7.95%19.16M | -12.22%7.88M | 68.54%52.76M | 45.14%34.36M | 43.64%20.81M | 169.59%8.98M | 63.28%31.3M | 61.67%23.67M |
Credit Impairment Loss | 43.34%-19.36M | 7.89%-16.52M | 12.05%-13.66M | 152.64%3.17M | -69.15%-34.17M | -153.14%-17.94M | -319.88%-15.53M | -580.95%-6.02M | 7.13%-20.2M | -5.14%-7.09M |
Asset Impairment Loss | 82.36%-3.42M | 57.92%-3.4M | -936.47%-6.74M | -144.92%-1.22M | -38,376.04%-19.41M | 61.80%-8.07M | 105.85%805.41K | 6.60%2.73M | 99.41%-50.44K | -495.63%-21.13M |
Other net revenue | 74.64%-10.17M | 26.94%-11.8M | -84.45%-15.79M | 10,562.65%4.38M | -738.40%-40.1M | -190.96%-16.15M | -5.13%-8.56M | -99.54%41.1K | 164.46%6.28M | 7.18%-5.55M |
Fair value change income | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
Invest income | -31.83%5.54M | -1.05%4.76M | -0.39%3.31M | 9.19%1.75M | -7.91%8.12M | -22.01%4.81M | 201,831.40%3.32M | 1,182.25%1.61M | -39.33%8.82M | 4,092.84%6.16M |
Net open hedge income | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
-Including: Investment income associates | -120.05%-39.89K | ---- | 9.79%523.93K | ---- | -82.34%198.97K | ---- | 29,068.14%477.19K | ---- | 189.89%1.13M | ---84.37K |
Exchange income | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
Asset deal income | -123.81%-41.46K | -144.49%-44.73K | -99.81%191.57 | -102.71%-2.79K | 1,613.86%174.16K | 889.52%100.56K | --102.99K | --102.99K | --10.16K | --10.16K |
Other revenue | 37.34%7.12M | -31.19%3.41M | -52.69%1.3M | -57.57%688.67K | -70.71%5.18M | -69.94%4.96M | -70.64%2.74M | -67.14%1.62M | 193.45%17.7M | 269.48%16.49M |
Operating profit | 17.09%392.07M | 8.18%229.14M | 50.18%152.43M | 3.15%31.81M | 35.13%334.84M | 46.11%211.8M | -4.90%101.5M | 39.54%30.84M | 32.19%247.79M | 24.47%144.96M |
Add:Non operating Income | -1.79%28.95K | -31.01%20.33K | 1.92%10.6K | --1.6K | 2,947,530.00%29.48K | --29.48K | --10.4K | ---- | -100.00%1 | ---- |
Less:Non operating expense | -16.98%1.31M | -67.48%467.38K | 22.78%404.75K | -83.18%31.35K | -73.72%1.58M | -75.82%1.44M | -45.37%329.66K | -69.04%186.41K | 558.93%6.02M | 641.94%5.94M |
Total profit | 17.25%390.78M | 8.69%228.69M | 50.26%152.04M | 3.68%31.78M | 37.85%333.29M | 51.35%210.4M | -4.66%101.18M | 42.58%30.65M | 29.55%241.77M | 20.18%139.02M |
Less:Income tax cost | 12.80%55.8M | 14.59%40.95M | 61.36%31.39M | -6.19%4.77M | 27.08%49.46M | 34.43%35.73M | 2.06%19.45M | 113.73%5.08M | 46.86%38.92M | 144.43%26.58M |
Net profit | 18.03%334.98M | 7.49%187.74M | 47.62%120.65M | 5.64%27.01M | 39.92%283.82M | 55.34%174.67M | -6.13%81.73M | 33.73%25.57M | 26.68%202.85M | 7.29%112.44M |
Net profit from continuing operation | 18.03%334.98M | 7.49%187.74M | 47.62%120.65M | 5.64%27.01M | 39.92%283.82M | 55.34%174.67M | -6.13%81.73M | 33.73%25.57M | 26.68%202.85M | 7.29%112.44M |
Net income from discontinuing operating | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
Less:Minority Profit | 58.67%1.74M | -26.99%603.08K | 59.97%838.42K | 44.49%379.28K | 41.67%1.1M | 2,035.40%826.06K | 8,090.35%524.11K | 1,424.78%262.5K | 1,277.46%774.44K | 167.22%38.68K |
Net profit of parent company owners | 17.87%333.24M | 7.65%187.14M | 47.54%119.81M | 5.24%26.63M | 39.91%282.73M | 54.66%173.84M | -6.74%81.2M | 32.22%25.31M | 26.14%202.07M | 7.20%112.4M |
Earning per share | ||||||||||
Basic earning per share | 16.33%0.57 | 6.67%0.32 | 45.00%0.29 | 0.00%0.06 | 0.00%0.49 | 11.11%0.3 | -4.76%0.2 | 20.00%0.06 | -5.77%0.49 | -20.59%0.27 |
Diluted earning per share | 19.15%0.56 | 6.67%0.32 | 45.00%0.29 | 0.00%0.06 | -4.08%0.47 | 11.11%0.3 | -4.76%0.2 | 20.00%0.06 | -5.77%0.49 | -20.59%0.27 |
Other composite income | 0 | |||||||||
Other composite income of parent company owners | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
Other composite income of minority owners | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
Total composite income | 18.03%334.98M | 7.49%187.74M | 47.62%120.65M | 5.64%27.01M | 39.92%283.82M | 55.34%174.67M | -6.13%81.73M | 33.73%25.57M | 26.68%202.85M | 7.29%112.44M |
Total composite income of parent company owners | 17.87%333.24M | 7.65%187.14M | 47.54%119.81M | 5.24%26.63M | 39.91%282.73M | 54.66%173.84M | -6.74%81.2M | 32.22%25.31M | 26.14%202.07M | 7.20%112.4M |
Total composite income of minority owners | 58.67%1.74M | -26.99%603.08K | 59.97%838.42K | 44.49%379.28K | 41.67%1.1M | 2,035.40%826.06K | 8,090.35%524.11K | 1,424.78%262.5K | 1,277.46%774.44K | 167.22%38.68K |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- |
Auditor | China Audit Zhonghuan Certified Public Accountants Co., Ltd. (Special General Partnership) | -- | -- | -- | China Audit Zhonghuan Certified Public Accountants Co., Ltd. (Special General Partnership) | -- | -- | -- | China Audit Zhonghuan Certified Public Accountants Co., Ltd. (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.